Now live: Pro — the full 13F research suite for serious investorsSee pricing →
Nan Fung Group Holdings Ltd

Q4 2023 · 13F-HR

Nan Fung Group Holdings Ltdholdings as filed

Filed 2024-02-13 · accession 0001012975-24-000077

$160.6M
Reported value
39
Positions
2023-12-31
Period end
View analyzed profile →PRO

Holdings as filed

CUSIPTickerIssuerValue% port.SharesClassVoting
48576A100KARUNA THERAPEUTICS INC$71.4M44.5%225,688CommonSOLE
452327109ILMNILLUMINA INC$16.6M10.3%119,196CommonSOLE
413197104HRMYHARMONY BIOSCIENCES HLDGS IN$11.9M7.42%368,665CommonSOLE
H5870P102OCSOCULIS HOLDING AG$5.8M3.63%518,933CommonSOLE
30223G102EXAIEUREXSCIENTIA PLC$5.5M3.43%859,892CommonSOLE
02083G100NVLSEURALPINE IMMUNE SCIENCES INC$5.0M3.13%263,940CommonSOLE
98420N105XENEXENON PHARMACEUTICALS INC$4.9M3.06%106,680CommonSOLE
83444K105SLGCUSDSOMALOGIC INC$4.3M2.67%1,696,558CommonSOLE
N5749R1002GHMERUS N V$3.8M2.35%137,038CommonSOLE
483497103KALVKALVISTA PHARMACEUTICALS INC$3.7M2.32%304,277CommonSOLE
604749101MIRMMIRUM PHARMACEUTICALS INC$2.8M1.77%96,100CommonSOLE
69404D108PACBPACIFIC BIOSCIENCES CALIF IN$2.7M1.68%274,488CommonSOLE
07725L102ONCBEIGENE LTD$2.2M1.35%12,022CommonSOLE
45337C102INCYINCYTE CORP$2.0M1.25%32,022CommonSOLE
374163103GERNGERON CORP$1.9M1.20%913,550CommonSOLE
76243J105RYTMRHYTHM PHARMACEUTICALS INC$1.8M1.15%40,070CommonSOLE
753018100RANIRANI THERAPEUTICS HLDGS INC$1.6M1.02%493,584CommonSOLE
76029N106REPLREPLIMUNE GROUP INC$1.6M0.97%184,739CommonSOLE
30161Q104EXELEXELIXIS INC$1.5M0.96%64,200CommonSOLE
097702104BOLT1EURBOLT BIOTHERAPEUTICS INC$1.3M0.81%1,166,952CommonSOLE
008064107AEROVATE THERAPEUTICS INC$1.1M0.68%47,936CommonSOLE
12674W109CABACABALETTA BIO INC$1.1M0.67%47,150CommonSOLE
004225108ACADACADIA PHARMACEUTICALS INC$938,7990.58%29,984CommonSOLE
29384C108TRDAENTRADA THERAPEUTICS INC$740,6470.46%49,082CommonSOLE
00166B105ALXOALX ONCOLOGY HLDGS INC$624,6360.39%41,950CommonSOLE
09077A106BMEABIOMEA FUSION INC$580,8000.36%40,000CommonSOLE
04016X101ARGXARGENX SE$544,0150.34%1,430CommonSOLE
04746L104ATHIRA PHARMA INC$437,4000.27%180,000CommonSOLE
270087208EARGO INC$383,0710.24%147,904CommonSOLE
23306J101DBV TECHNOLOGIES S A$353,4410.22%370,950CommonSOLE
09061G101BMRNBIOMARIN PHARMACEUTICAL INC$348,5580.22%3,615CommonSOLE
558868105MDGLMADRIGAL PHARMACEUTICALS INC$273,4910.17%1,182CommonSOLE
N01045108AFFIMED N V$232,7950.14%372,472CommonSOLE
09058V103BCRXBIOCRYST PHARMACEUTICALS INC$106,9040.07%17,847CommonSOLE
36338D108GRTXGALERA THERAPEUTICS INC$89,1630.06%613,223CommonSOLE
00288U106ABCLABCELLERA BIOLOGICS INC$71,4950.04%12,521CommonSOLE
50015M109KODKODIAK SCIENCES INC$59,6510.04%19,622CommonSOLE
31572Q808FGENEURFIBROGEN INC$55,0450.03%62,106CommonSOLE
157085101CERSCERUS CORP$30,6120.02%14,172CommonSOLE

Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.